Lyra Therapeutics (LYRA) Total Liabilities (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Total Liabilities of $46.8 million in Q4 2025, down 2.52% on a QoQ basis from $48.0 million in Q3 2025, and down 14.48% YoY from $54.8 million in Q4 2024.
Lyra Therapeutics (LYRA) Total Liabilities (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Total Liabilities for 7 consecutive years, with $46.8 million the latest figure, recorded in Q4 2025.
- Total Liabilities for Q4 2025 came in at $46.8 million, down 14.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $46.8 million (down 14.48% YoY), and the FY2025 annual result was $46.8 million, down 14.48% from the prior year.
- Total Liabilities for Q4 2025 stood at $46.8 million, down from $48.0 million in the prior quarter.
- The five-year high for Total Liabilities was $64.0 million in Q1 2024, with the low at $5.4 million in Q1 2021.
- A 5-year average of $37.6 million and a median of $32.8 million in 2022 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities fell 26.99% in 2021 and soared 348.9% in 2022, its largest moves.
- Lyra Therapeutics' Total Liabilities stood at $20.6 million in 2021, then surged by 42.15% to $29.2 million in 2022, then jumped by 82.04% to $53.2 million in 2023, then climbed by 2.96% to $54.8 million in 2024, then declined by 14.48% to $46.8 million in 2025.
- The last three Total Liabilities figures came in at $46.8 million (Q4 2025), $48.0 million (Q3 2025), and $51.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 46.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.83 Mn |
| Sep 30, 2025 | 48.04 Mn |
| Jun 30, 2025 | 50.95 Mn |
| Mar 31, 2025 | 52.44 Mn |
| Dec 31, 2024 | 54.75 Mn |
| Sep 30, 2024 | 58.14 Mn |
| Jun 30, 2024 | 63.61 Mn |
| Mar 31, 2024 | 64.02 Mn |
| Dec 31, 2023 | 53.18 Mn |
| Sep 30, 2023 | 36.34 Mn |
| Jun 30, 2023 | 27.10 Mn |
| Mar 31, 2023 | 27.78 Mn |
| Dec 31, 2022 | 29.21 Mn |
| Sep 30, 2022 | 26.24 Mn |
| Jun 30, 2022 | 23.79 Mn |
| Mar 31, 2022 | 24.09 Mn |
| Dec 31, 2021 | 20.55 Mn |
| Sep 30, 2021 | 20.57 Mn |
| Jun 30, 2021 | 18.83 Mn |
| Mar 31, 2021 | 5.37 Mn |